Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELAPR002f Injectable · 1 trial · 1 indication
The ACSS is a 5-point photonumeric scale that assesses the appearance of cheek smoothness vs coarseness where 0=none and 4=extreme. A responder is a participant with at least 1-grade improvement from baseline in ACSS.
The AFLS is a 5-point photonumeric scale that assesses the appearance of fine lines where 0=none and 4=diffuse superficial lines. A responder is a participant with at least 1-grade improvement from baseline in AFLS.
| Arm | Type | Description |
|---|---|---|
| ELAPR002f Injectable Gel | EXPERIMENTAL | Participants will receive 3 treatment sessions 1 month apart of ELAPR002f injectable gel and will be followed for 4 months. |
| Name | Type | Description |
|---|---|---|
| ELAPR002f Injectable Gel | DEVICE | Intradermal Injections |
Inclusion Criteria: * Participants in general good health, in the opinion of the investigator, with no known active COVID-19 infection, seeking improvement of facial skin quality. * Moderate or severe (symmetric grade 2 or 3 on the Allergan Fine Lines Scale \[AFLS\] and Allergan Cheek Smoothness Sc...
ELAPR002f Injectable is an investigational injectable gel being studied for the treatment of atrophic acne scars and for the improvement of skin quality in adults. It is being developed by AbbVie Inc. (ABBV) and is currently in clinical trials for these dermatological indications.
ELAPR002f Injectable is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the safety and effectiveness of this injectable gel for dermatological uses.
ELAPR002f Injectable is in Phase 2 and Phase 3 clinical trials. It is an investigational product and has not been approved by regulatory authorities. Studies are ongoing to assess its safety and effectiveness for treating atrophic acne scars and improving skin quality.
ELAPR002f Injectable has been studied in several clinical trials. NCT05995340 evaluated the gel in 157 participants with atrophic acne scars in Canada and Germany. NCT06151535 assessed skin quality improvement in 30 adults in Italy. NCT07207369 is currently recruiting 395 participants with acne scars in the United States.
ELAPR002f Injectable is the injectable formulation of the product referred to as ELAPR002f. The clinical trials listed for this asset use the name ELAPR002f Injectable Gel, indicating it is a gel formulation intended for injection.